Raymond L Benza

List of Publications by Year
in descending order

219 papers	15,959 citations	28190 55 h-index	16605 123 g-index
234 all docs	234 docs citations	234 times ranked	10493 citing authors

#	Article	IF	Citations
1	Predicting Survival in Pulmonary Arterial Hypertension. Circulation, 2010, 122, 164-172.	1.6	1,353
2	Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 287, 1541.	3.8	1,050
3	Pulmonary Arterial Hypertension. Chest, 2010, 137, 376-387.	0.4	1,018
4	The VIVA Trial. Circulation, 2003, 107, 1359-1365.	1.6	964
5	An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry. Chest, 2012, 142, 448-456.	0.4	926
6	Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2004, 291, 1963.	3.8	603
7	Heart failure etiology and response tomilrinone in decompensated heart failure. Journal of the American College of Cardiology, 2003, 41, 997-1003.	1.2	490
8	Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 55, 1915-1922.	1.2	484
9	The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Chest, 2012, 141, 354-362.	0.4	448
10	Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59.	1.2	432
11	Predicting Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2019, 156, 323-337.	0.4	408
12	Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest, 2015, 148, 1043-1054.	0.4	368
13	The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States. Chest, 2011, 139, 128-137.	0.4	303
14	Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension. Chest, 2006, 129, 683-688.	0.4	284
15	Clinical risk factors for portopulmonary hypertension. Hepatology, 2008, 48, 196-203.	3.6	239
16	Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S67-S77.	1.2	230
17	Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology, 2002, 40, 970-975.	1.2	228
18	Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1586-1589.	2.5	221

#	Article	IF	Citations
19	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adultâ€”a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 913-933.	0.3	210
20	Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 835-842.	2.5	206
21	Role of Cardiac Magnetic Resonance Imaging in the Management of Patients With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2008, 52, 1683-1692.	1.2	178
22	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801906.	3.1	144
23	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest, 2021, 159, 337-346.	0.4	137
24	Infection in ventricular assist devices: prevention and treatment. Annals of Thoracic Surgery, 2003, 75, S48-S57.	0.7	132
25	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
26	Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry. Chest, 2014, 146, 1494-1504.	0.4	121
27	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology, 2010, 149, 426-435.	1.2	114
28	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	3.1	113
29	Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: A Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. Journal of Heart and Lung Transplantation, 2015, 34, 356-361.	0.3	111
30	Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis. Journal of Heart and Lung Transplantation, 2007, 26, 584-592.	0.3	107
31	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. Journal of Heart and Lung Transplantation, 2015, 34, 362-368.	0.3	102
32	Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension. Chest, 2008, 134, 775-782.	0.4	99
33	Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. Journal of Heart and Lung Transplantation, 2005, 24, 2196-2201.	0.3	98
34	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333.	0.3	98
35	Serum Endostatin Is a Genetically Determined Predictor of Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 208-218.	2.5	92
36	Infection during circulatory support with ventricular assist devices. Annals of Thoracic Surgery, 1999, 68, 711-716.	0.7	83

#	Article	IF	Citations
37	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	3.1	82
38	Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1345-1354.	2.5	82
39	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. Journal of Heart and Lung Transplantation, 2011, 30, 982-989.	0.3	80
40	Palliation of allograft vasculopathy with transluminal angioplasty. Journal of the American College of Cardiology, 2004, 43, 1973-1981.	1.2	79
41	Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. Chest, 2013, 144, 1521-1529.	0.4	75
42	Significance of Residual Mitral Regurgitation After Continuous Flow LeftÂVentricular Assist Device Implantation. JACC: Heart Failure, 2017, 5, 81-88.	1.9	68
43	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	3.1	68
44	Polyphenolics Increase t-PA and u-PA Gene Transcription in Cultured Human Endothelial Cells. Alcoholism: Clinical and Experimental Research, 2001, 25, 155-162.	1.4	66
45	Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies. Journal of Heart and Lung Transplantation, 2007, 26, 437-446.	0.3	66
46	Analysis of the Lung Allocation Score Estimation of Risk of Death in Patients With Pulmonary Arterial Hypertension Using Data From the REVEAL Registry. Transplantation, 2010, 90, 298-305.	0.5	66
47	The impact of arrhythmias in acute heart failure. Journal of Cardiac Failure, 2004, 10, 279-284.	0.7	64
48	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	1.2	62
49	Sitaxsentan Treatment for Patients With Pulmonary Arterial Hypertension Discontinuing Bosentan. Journal of Heart and Lung Transplantation, 2007, 26, 63-69.	0.3	61
50	Genotype-Specific Transcriptional Regulation of PAI-1 Expression by Hypertriglyceridemic VLDL and Lp(a) in Cultured Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3215-3223.	1.1	59
51	Genetic Testing in Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 50, 727-737.	1.2	59
52	Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension*: Long-term Efficacy and Combination With Bosentan. Chest, 2008, 134, 139-145.	0.4	59
53	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
54	Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?. Journal of the American College of Cardiology, 2011, 57, 1053-1061.	1.2	56

#	Article	IF	Citations
55	Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. Journal of Heart and Lung Transplantation, 2015, 34, 329-337.	0.3	56
56	Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology, 2019, 4, 556.	3.0	53
57	Gene Polymorphisms for Plasminogen Activator Inhibitor-1/Tissue Plasminogen Activator and Development of Allograft Coronary Artery Disease. Circulation, 1998, 98, 2248-2254.	1.6	52
58	Efficacy of Bosentan in a Small Cohort of Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Chest, 2006, 129, 1009-1015.	0.4	49
59	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 365-375.	0.3	49
60	Post-Heart Transplant Diastolic Dysfunction Is a Risk Factor for Mortality. Journal of the American College of Cardiology, 2007, 50, 1064-1069.	1.2	47
61	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. JACC: Heart Failure, 2018, 6, 771-779.	1.9	45
62	Sex-Based Differences in Left Ventricular Assist Device Utilization. Circulation: Heart Failure, 2019, 12, e006082.	1.6	44
63	A New Bayesian Network-Based Risk Stratification Model for Prediction of Short-Term and Long-Term LVAD Mortality. ASAIO Journal, 2015, 61, 313-323.	0.9	43
64	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 1179-1186.	0.3	42
65	Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension. Chest, 2019, 156, 53-63.	0.4	42
66	Right Ventricular Pressure Waveform and Wave Reflection Analysis in Patients With Pulmonary Arterial Hypertension. Chest, 2007, 132, 37-43.	0.4	40
67	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2018, 154, 126-135.	0.4	40
68	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.3	39
69	Cardiomyopathy in a carrier of duchenneâ€™s muscular dystrophy. Journal of Heart and Lung Transplantation, 2001, 20, 781-784.	0.3	38
70	Creation of a Model Comparing 6-Minute Walk Test to Metabolic Equivalent in Evaluating Treatment Effects in Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 732-738.	0.3	38
71	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. Chest, 2009, 135, 1470-1475.	0.4	38
72	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 2020, 56, 2000008.	3.1	38

#	Article	IF	Citations
73	Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2019, 291, 134-139.	0.8	37
74	Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 780-788.	0.3	36
75	Imatinib in Pulmonary Arterial Hypertension: Câ€Kit Inhibition. Pulmonary Circulation, 2014, 4, 452-455.	0.8	35
76	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. Journal of Heart and Lung Transplantation, 2014, 33, 521-527.	0.3	33
77	Genotype-Specific Transcriptional Regulation of PAI-1 Gene by Insulin, Hypertriglyceridemic VLDL, and Lp(a) in Transfected, Cultured Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1803-1809.	1.1	32
78	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. Chest, 2019, 156, 1176-1186.	0.4	32
79	One-year experience with intravenous treprostinil for pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2013, 32, 889-896.	0.3	31
80	Thrombin Decreases the Urokinase Receptor and Surface-Localized Fibrinolysis in Cultured Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 410-419.	1.1	30
81	Treatment of end-stage heart disease with outpatient ventricular assist devices. Annals of Thoracic Surgery, 2002, 73, 1489-1494.	0.7	30
82	Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Cardiovascular Therapeutics, 2013, 31, 38-44.	1.1	29
83	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. Journal of Heart and Lung Transplantation, 2018, 37, 836-843.	0.3	29
84	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.	0.3	29
85	Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004757.	0.9	29
86	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 696-705.	0.3	28
87	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 613-622.	1.5	27
88	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	2.5	27
89	Hypertriglyceridemic VLDL Decreases Plasminogen Binding to Endothelial Cells and Surface-Localized Fibrinolysis. Biochemistry, 1996, 35, 6080-6088.	1.2	26
90	Cardiac transplant patients response to the 31P MRS stress test. Journal of Heart and Lung Transplantation, 2002, 21, 522-529.	0.3	25

#	Article	IF	Citations
91	Assessing risk in pulmonary arterial hypertension: what we know, what we don't. European Respiratory Journal, 2017, 50, 1701353.	3.1	25
92	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Journal of Heart and Lung Transplantation, 2019, 38, 43-50.	0.3	25
93	Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathyâ€"preliminary observations from a highâ€volume transplant centre. ESC Heart Failure, 2015, 2, 150-159.	1.4	24
94	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: Insights from a wireless pulmonary artery pressure monitoring system. Journal of Heart and Lung Transplantation, 2015, 34, 438-447.	0.3	24
95	Pulmonary Hypertension Associated with Sickle Cell Disease: Pathophysiology and Rationale for Treatment. Lung, 2008, 186, 247-254.	1.4	23
96	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 731-739.	0.7	23
97	Retrospective Validation of the REVEAL 2.0ÂRisk Score With the Australian and NewÂZealand Pulmonary Hypertension Registry Cohort. Chest, 2020, 157, 162-172.	0.4	23
98	Intrapulmonary Shunting in Primary Pulmonary Hypertension. Chest, 1998, 114, 334-336.	0.4	21
99	The Pathophysiology of Endothelin in Complications After Solid Organ Transplantation. Transplantation, 2012, 94, 885-893.	0.5	21
100	Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. ASAIO Journal, 2017, 63, 251-256.	0.9	20
101	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Current Hypertension Reports, 2019, 21, 45.	1.5	20
102	Therapeutic angiogenesis: review of current concepts and future directions. Journal of Heart and Lung Transplantation, 2003, 22, 370-382.	0.3	19
103	Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2008, 27, 610-615.	0.3	19
104	Î±-Galactosidase A Expressed in the Salivary Glands Partially Corrects Organ Biochemical Deficits in the Fabry Mouse Through Endocrine Trafficking. Human Gene Therapy, 2011, 22, 293-301.	1.4	19
105	Identification of a 251-bp Fragment of the PAI-1 Gene Promoter That Mediates the Ethanol-Induced Suppression of PAI-1 Expression. Alcoholism: Clinical and Experimental Research, 2001, 25, 629-636.	1.4	18
106	Tissue Doppler Assessment of Longitudinal Right and Left Ventricular Strain and Strain Rate in Pulmonary Artery Hypertension. Echocardiography, 2006, 23, 872-879.	0.3	18
107	TLR4 regulates pulmonary vascular homeostasis and remodeling via redox signaling. Frontiers in Bioscience - Landmark, 2016, 21, 397-409.	3.0	18
108	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. Journal of Heart and Lung Transplantation, 2018, 37, 948-955.	0.3	18

#	Article	IF	Citations
109	Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1407-1415.	2.5	18
110	Expression of Plasminogen Activator Inhibitor Type I in Genotyped Human Endothelial Cell Cultures: Genotype-specific Regulation by Insulin. Thrombosis and Haemostasis, 1999, 82, 1504-1509.	1.8	17
111	Ethanol-Induced Up-Regulation of the Urokinase Receptor In Cultured Human Endothelial Cells. Alcoholism: Clinical and Experimental Research, 2001, 25, 163-170.	1.4	17
112	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	2.5	17
113	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.3	17
114	Harvest of pulmonary artery endothelial cells from patients undergoing right heart catheterization. Journal of Heart and Lung Transplantation, 2013, 32, 746-749.	0.3	16
115	ThreeâĐimensional Micro Computed Tomography Analysis of the Lung Vasculature and Differential Adipose Proteomics in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 586-596.	0.8	16
116	Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. Journal of Heart and Lung Transplantation, 2021, 40, 172-182.	0.3	16
117	Relative Perioperative Bradycardia Does Not Lead to Adverse Outcomes After Cardiac Transplantation. American Journal of Transplantation, 2003, 3, 484-491.	2.6	15
118	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22.	1.3	15
119	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.3	15
120	Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease. Journal of Thrombosis and Thrombolysis, 1998, 5, 143-150.	1.0	14
121	Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thrombosis and Haemostasis, 2012, 108, 1049-1060.	1.8	14
122	Salvage Peripheral Extracorporeal Membrane Oxygenation Using Cobe RevolutionÂ® Centrifugal Pump as a Bridge to Decision for Acute Refractory Cardiogenic Shock. Journal of Cardiac Surgery, 2012, 27, 521-527.	0.3	14
123	MicroCT analysis of vascular morphometry: a comparison of right lung lobes in the SUGEN/hypoxic rat model of pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 522-530.	0.8	14
124	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. International Journal of Cardiology, 2018, 254, 299-301.	0.8	14
125	A Novel Compound, â€œFA-1â€•Isolated from Prunus mume, Protects Human Bronchial Epithelial Cells and Keratinocytes from Cigarette Smoke Extract-Induced Damage. Scientific Reports, 2018, 8, 11504.	1.6	14
126	Transforming Growth Factor-beta Polymorphisms and Cardiac Allograft Rejection. Journal of Heart and Lung Transplantation, 2009, 28, 1057-1062.	0.3	13

#	Article	IF	Citations
127	Replacing a phosphodiesteraseâ€5Âinhibitor with riociguat in patients with connective tissue diseaseâ€associated pulmonary arterial hypertension: a case series. Pulmonary Circulation, 2017, 7, 741-746.	0.8	13
128	Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	13
129	Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 843-845.	2.5	12
130	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. Advances in Pulmonary Hypertension, 2018, 16, 125-135.	0.1	12
131	Hemodynamic Ranges During Daily Activities and Exercise Testing in Patients With Pulmonary Arterial Hypertension. Journal of Cardiac Failure, 2014, 20, 485-491.	0.7	11
132	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	1.6	11
133	Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. Journal of Heart and Lung Transplantation, 2003, 22, 515-518.	0.3	10
134	Transitioning from Parenteral Treprostinil to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 116-120.	0.8	10
135	In Situ Expression of Bclâ€2Âin Pulmonary Artery Endothelial Cells Associates with Pulmonary Arterial Hypertension Relative to Heart Failure with Preserved Ejection Fraction. Pulmonary Circulation, 2016, 6, 551-556.	0.8	10
136	Bosentanâ€based, treatâ€toâ€target therapy in patients with pulmonary arterial hypertension: results from the COMPASSâ€3 study. Pulmonary Circulation, 2018, 8, 1-13.	0.8	10
137	Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. ASAIO Journal, 2019, 65, 436-441.	0.9	10
138	Hypertriglyceridemic VLDL Downregulates Tissue Plasminogen Activator Gene Transcription Through cis -Repressive Region(s) in the Tissue Plasminogen Activator Promoter in Cultured Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1675-1681.	1.1	9
139	Pulmonary hypertension in potential heart transplant recipients. Current Opinion in Organ Transplantation, 2015, 20, 570-576.	0.8	9
140	Phosphodiesterase type 5Âinhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 539-542.	0.8	9
141	Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers, 2009, 14, 156-160.	0.9	8
142	Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration. Annals of the American Thoracic Society, 2015, 12, 269-273.	1.5	8
143	Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. Annals of Thoracic Surgery, 2019, 108, 1178-1182.	0.7	8
144	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8

#	Article	IF	Citations
145	Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression Pattern. Journal of Heart and Lung Transplantation, 2007, 26, 494-497.	0.3	7
146	Pulmonary hypertension: chapters of innovation and tribulation. European Heart Journal, 2012, 33, 961-968.	1.0	7
147	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation, 2019, 9, 204589401985169.	0.8	7
148	Does Late Gadolinium Enhancement still have Value? Right Ventricular Internal Mechanical Work, E/E and Late Gadolinium Enhancement as Prognostic Markers in Patients with Advanced Pulmonary Hypertension via Cardiac MRI. Cardiology Research and Cardiovascular Medicine, 2017, 2017, .	0.0	7
149	Hemodynamic Response to Treatment of Iron Deficiency Anemia in Pulmonary Arterial Hypertension: Longitudinal Insights from an Implantable Hemodynamic Monitor. Pulmonary Circulation, 2016, 6, 616-618.	0.8	6
150	sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. Respiratory Medicine, 2017, 122, S28-S34.	1.3	6
151	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	0.8	6
152	PPARÎ³ increases HUWE1 to attenuate NF-Î²B/p65 and sickle cell disease with pulmonary hypertension. Blood Advances, 2021, 5, 399-413.	2.5	6
153	Aortic graft transplantation in mice. Journal of Heart and Lung Transplantation, 2002, 21, 1319-1321.	0.3	5
154	Management of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2014, 16, 501.	1.5	5
155	Successful Treatment of Acute Left Ventricular Assist Device Thrombosis and Cardiogenic Shock with Intraventricular Thrombolysis and a Tandem Heart. ASAIO Journal, 2015, 61, 98-101.	0.9	5
156	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 606-618.	0.8	5
157	Integrated use of cardiac MRI and the CardioMEMSâ„¢ HF system in PAH: the utility of coincident pressure and volume in RV failureâ€"the NHLBI-VITA trial. Cardiovascular Diagnosis and Therapy, 2019, 9, 492-501.	0.7	5
158	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2020, 10, 1-8.	0.8	5
159	Application of the REVEAL risk score calculator 2.0 in the PATENT study. International Journal of Cardiology, 2021, 332, 189-192.	0.8	5
160	Ethanol-Induced Up-Regulation of Candidate Plasminogen Receptor Annexin II in Cultured Human Endothelial Cells. Alcoholism: Clinical and Experimental Research, 2000, 24, 754-761.	1.4	5
161	REVEAL REGISTRY: BASELINE CHARACTERISTICS OF THE FIRST 1,226 ENROLLED PATIENTS. Chest, 2007, 132, 473B.	0.4	4
162	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. Gastroenterology Insights, 2012, 4, 2.	0.7	4

#	Article	IF	Citations
163	Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	0.8	4
164	Ambulatory Hemodynamic Monitoring in the Management of Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2014, 13, 81-85.	0.1	4
165	Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. Journal of Heart and Lung Transplantation, 2022, 41, 411-420.	0.3	4
166	Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. Journal of Thrombosis and Thrombolysis, 1998, 5, 113-118.	1.0	3
167	Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology, 2014, 7, 415-421.	1.3	3
168	In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy. Human Gene Therapy, 2017, 28, 681-689.	1.4	3
169	Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 227-230.	0.3	3
170	The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study. JMIR Research Protocols, 2021, 10, e25397.	0.5	3
171	Commentary: non-immunologic vascular failure of the transplanted heart. Journal of Heart and Lung Transplantation, 2003, 22, 241-243.	0.3	2
172	Transmyocardial and percutaneous myocardial revascularization: current concepts and future directions. Journal of Heart and Lung Transplantation, 2003, 22, 837-842.	0.3	2
173	ONE YEAR EXPERIENCE WITH INTRAVENOUS TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS. Chest, 2005, 128, 160S.	0.4	2
174	Safety and Efficacy of Ibutilide in Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 505-507.	0.3	2
175	The role of fibrinolytic genes and proteins in the development of allograft vascular disease. Journal of Heart and Lung Transplantation, 2011, 30, 935-44.	0.3	2
176	An Aggressive, Targeted Perioperative Management Strategy Results in Low Rates of Postoperative Right Ventricular Failure After Left Ventricular Assist Device Implantation. Journal of Cardiac Failure, 2012, 18, S45.	0.7	2
177	Heart Failure Hospitalizations are Reduced in Heart Failure Patients With Comorbid Pulmonary Hypertension Using a Wireless Implanted Pulmonary Artery Pressure Monitoring System. Journal of Cardiac Failure, 2012, 18, S99.	0.7	2
178	Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, xxi-xxii.	1.0	2
179	Spontaneous microbubbles in the aortic root and thrombosis of a continuous-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 550-551.	0.3	2
180	Assessing hemodynamic response to submaximal exercise in pulmonary arterial hypertension patients using an implantable hemodynamic monitor. Journal of Heart and Lung Transplantation, 2021, 40, 430-434.	0.3	2

#	Article	IF	Citations
181	Computational Simulator Models and Invasive Hemodynamic Monitoring as Tools for Precision Medicine in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 82.	1.0	2
182	GOAL-DIRECTED COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION (PAH): STUDY DESIGN OF COMPASS-3. Chest, 2007, 132, 633A.	0.4	1
183	Predictors of 30-Day Hospital Readmissions in Patients with Heart Failure (HF). Journal of Cardiac Failure, 2011, 17, S86.	0.7	1
184	Concomitant cat scratch disease and squamous cell carcinoma in a cardiac transplant. Gastroenterology Insights, 2012, 4, e2.	0.7	1
185	The Relationship Between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients With PAH Not Reaching Treatment Goals With Phosphodiesterase 5 Inhibitors. Chest, 2016, 150, 1316A.	0.4	1
186	IMPLEMENTATION AND OUTCOMES OF A PULMONARY EMBOLISM RESPONSE TEAM: A SINGLE CENTER EXPERIENCE. Journal of the American College of Cardiology, 2018, 71, A1943.	1.2	1
187	Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization. Journal of Visualized Experiments, 2019, , .	0.2	1
188	RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors. , 2016, , .		1
189	REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal. , 2017, , .		1
190	Application of the REVEAL risk score calculator 2.0 in the CHEST study. Respiratory Medicine, 2022, 195, 106783.	1.3	1
191	Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	0.7	1
192	RISK FACTORS FOR COPD IN LIVER TRANSPLANT CANDIDATES. Chest, 2007, 132, 427A.	0.4	0
193	627: Cytokine SNPS and their relationship to the development of peripartum cardiomyopathy. American Journal of Obstetrics and Gynecology, 2008, 199, S180.	0.7	0
194	Plasma Myeloperoxidase Activity in Chronic Heart Failure. Journal of Cardiac Failure, 2009, 15, S37-S38.	0.7	0
195	Transitioning Patients From Inhaled Iloprost To Inhaled Treprostinil Sodium: An Interim Analysis. , 2010, , .		0
196	Use Of The REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator In Newly Diagnosed Patients. , 2010, , .		0
197	Clinical Worsening Of Pulmonary Arterial Hypertension: The COMPASS-3 Study. , 2010, , .		0
198	Differences Between Idiopathic Pulmonary Arterial Hypertension And Connective Tissue Disease-Associated Pulmonary Arterial Hypertension After 16 Weeks Of Bosentan Monotherapy: The COMPASS-3 Study. , 2010, , .		0

#	Article	IF	Citations
199	Transductional And Transcriptional Targeting Of AAV To The Pulmonary Vasculature. , 2011, , .		0
200	Angiogenesis-Related Genes And Risk Of Scleroderma-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
201	Long-Term Follow-Up In PAH Patients Dosed With Beraprost Sodium Modified Release (BPS-MR) Tablets, An Oral Twice Daily Prostacyclin Analogue. , 2011, , .		0
202	Late gadolinium enhancement in pulmonary hypertension predicts clinical events. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	1.6	0
203	Rationale and Study Design of the RESPITE Trial: Riociguat Clinical Effects Studied in Pulmonary Arterial Hypertension (PAH) Patients With Insufficient Treatment Response to PDE-5 Inhibitors (PDE-5i). Chest, 2015, 148, 923A.	0.4	0
204	Application of REVEAL Risk Score to Patients With PAH Receiving Riociguat in the PATENT-2 Study. Chest, 2015, 148, 930A.	0.4	0
205	The Relationship of Hemodynamics and Exercise Capacity With Response to Riociguat Therapy in the Respite Study of PAH Patients With an Insufficient Response to Phosphodiesterase 5 Inhibitors. Chest, 2017, 152, A1002-A1003.	0.4	0
206	Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study. Chest, 2017, 152, A1005-A1006.	0.4	0
207	Baseline Predictors of Clinical Response: A Post Hoc Analysis of the Ambition Trial. Chest, 2017, 152, A1052.	0.4	0
208	Response. Chest, 2018, 154, 1262-1264.	0.4	0
209	APPLICATION OF A BAYESIAN NETWORK MODEL TO PREDICT OUTCOMES IN PULMONARY ARTERIAL HYPERTENSION. Chest, 2018, 154, 1061A.	0.4	0
210	EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Chest, 2018, 154, 1065A-1066A.	0.4	0
211	EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2018, 154, 1062A-1064A.	0.4	0
212	Implementation and Outcomes of a Pulmonary Embolism Response Team: A Single Center Experience. Journal of Cardiac Failure, 2019, 25, S143.	0.7	0
213	A Comparative Analysis of Clinical Variables Associated with Hospitalization in Pulmonary Arterial Hypertension. Journal of Cardiac Failure, 2019, 25, S49.	0.7	0
214	The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. Methodist DeBakey Cardiovascular Journal, 2021, 17, 134.	0.5	0
215	Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i). , 2015, , .		0
216	Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study. , 2015, , .		0

#	Article	IF	Citations
217	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
218	Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study. , 2017, , .		0
219	Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease. International Journal of Cardiology Congenital Heart Disease, 2022, 8, 100354.	0.2	0